Myrtenol's Effectiveness against Hospital-Acquired Methicillin-Resistant <i>Staphylococcus aureus</i>: Targeting Antibiofilm and Antivirulence Properties.

ABSTRACT: The emergence of methicillin-resistant Staphylococcus aureus (MRSA) several years ago highlighted the challenge of multidrug-resistant infections, emphasizing the critical need for innovative treatment approaches. Myrtenol, known for its antibacterial and antibiofilm properties, holds promise as a potential treatment option. This study aimed to evaluate the effectiveness of myrtenol against MRSA. The collected MRSA isolates were assessed for antimicrobial susceptibility following the Clinical and Laboratory Standards Institute (CLSI) guidelines 2023. Biofilm formation by MRSA was evaluated using the tissue culture plate (TCP) technique. The minimal inhibitory concentration (MIC), minimal bactericidal concentration (MBC), and minimal biofilm inhibitory concentration (MBIC) of myrteno

SUBMITTER: Makled AF 

PROVIDER: S-EPMC11498983 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature